Moving the genetics of inflammatory bowel diseases from bench to bedside: First steps towards personalised medicine

Gut

Volumn 62, Issue 11, 2013, Pages 1531-1533

  Brand, Stephan ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BACTERIAL ANTIGEN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; JANUS KINASE 2; THIOPURINE METHYLTRANSFERASE; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADAPTIVE IMMUNITY; AGE DISTRIBUTION; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG MEGADOSE; ENTERITIS; ENZYME INHIBITION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; IL23R GENE; ILEUM DISEASE; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; INTESTINE RESECTION; INTESTINE STENOSIS; INTESTINE SURGERY; JAK2 GENE; MULTICENTER STUDY (TOPIC); NOD2 GENE; ONSET AGE; PATHOGENESIS; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SIGNAL TRANSDUCTION; SMOKING; TREATMENT OUTCOME; ULCERATIVE COLITIS;

CROHN'S DISEASE; IBD; IBD - GENETICS; IBD CLINICAL; IBD SURGERY;

CROHN DISEASE; FEMALE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84885634647     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-304151     Document Type: Article

References (15)

1. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010;42:1118-25.
2. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011;43:246-52.
3. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491: 119-24.
4. Cleynen I, Gonzalez JR, Figueroa C, et al. Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project. Gut 2013;62:1556-65.
5. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008;40:955-62.
6. Seiderer J, Brand S, Herrmann KA, et al. Predictive value of the CARD15 variant 1007fs for the diagnosis of intestinal stenoses and the need for surgery in Crohn's disease in clinical practice: results of a prospective study. Inflamm Bowel Dis 2006;12:1114-21. (Pubitemid 44847468)
7. Seiderer J, Schnitzler F, Brand S, et al. Homozygosity for the CARD15 frameshift mutation 1007fs is predictive of early onset of Crohn's disease with ileal stenosis, entero-enteral fistulas, and frequent need for surgical intervention with high risk of re-stenosis. Scand J Gastroenterol 2006;41:1421-32. (Pubitemid 44767495)
8. Jürgens M, Brand S, Laubender RP, et al. The presence of fistulas and NOD2 homozygosity strongly predict intestinal stenosis in Crohn's disease independent of the IL23R genotype. J Gastroenterol 2010;45:721-31.
9. Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 2009;58:1152-67.
10. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012;367:616-24.
11. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
12. Schnitzler F, Seiderer J, Stallhofer J, et al. Dominant disease-causing effect of NOD2 mutations in a family with all family members affected by Crohn's disease. Inflamm Bowel Dis 2012;18:395-6.
13. Adler J, Rangwalla SC, Dwamena BA, et al. The prognostic power of the NOD2 genotype for complicated Crohn's disease: a meta-analysis. Am J Gastroenterol 2011;106:699-712.
14. Jürgens M, Laubender RP, Hartl F, et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol 2010;105:1811-19.
15. Kaser A, Zeissig S, Blumberg RS. Genes and environment: how will our concepts on the pathophysiology of IBD develop in the future? Dig Dis 2010;28:395-405.